Skip to content

Praxis Precision Medicines, Inc. PRAX Change in Lease Liabilities

Change in Lease Liabilities at other companies

Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-$608K-392%
TG Therapeutics logo
TG TherapeuticsTGTX
-$424K+21.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$1.85M-26.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$105.9M-41.7%
Net income-$92.6M-33.6%
EPS (diluted)-$3.20+2.7%

Balance sheet

See full
Cash & equivalents$536.7M+223%
Total debt$1.4M+31.3%
Total equity$1.4B+221%
Total assets$1.5B+205%

Cash flow

See full
Operating cash flow-$86.2M-62.5%
CapEx$62.0K
Free cash flow-$86.2M-62.6%

Valuation

See full
Market cap$7.87B+1,075%
Enterprise value$7.34B+1,309%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-35.3%-10.9pp
Debt / equity0.0×
Current ratio15.9×+7.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Praxis Precision Medicines, Inc.'s change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Praxis Precision Medicines, Inc.'s change in lease liabilities?
Praxis Precision Medicines, Inc. (PRAX) reported change in lease liabilities of -$101K in Q1 2026.
How has Praxis Precision Medicines, Inc.'s change in lease liabilities changed year-over-year?
Praxis Precision Medicines, Inc.'s change in lease liabilities increased by 66.7% year-over-year, from -$303K to -$101K.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.